Cargando…

Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy

INTRODUCTION: Clinical evidence for patients with synchronous brain oligometastatic non-small-cell lung carcinoma is limited. We aimed to summarize the clinical data of these patients to explore the survival prognostic factors for this population. METHODS: From September 1995 to July 2011, patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Hao, Xu, Jianlin, Yang, Haitang, Jin, Bo, Lou, Yuqing, Wu, Dan, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948689/
https://www.ncbi.nlm.nih.gov/pubmed/27471395
http://dx.doi.org/10.2147/OTT.S106696
_version_ 1782443313290280960
author Bai, Hao
Xu, Jianlin
Yang, Haitang
Jin, Bo
Lou, Yuqing
Wu, Dan
Han, Baohui
author_facet Bai, Hao
Xu, Jianlin
Yang, Haitang
Jin, Bo
Lou, Yuqing
Wu, Dan
Han, Baohui
author_sort Bai, Hao
collection PubMed
description INTRODUCTION: Clinical evidence for patients with synchronous brain oligometastatic non-small-cell lung carcinoma is limited. We aimed to summarize the clinical data of these patients to explore the survival prognostic factors for this population. METHODS: From September 1995 to July 2011, patients with 1–3 synchronous brain oligometastases, who were treated with stereotactic radiosurgery (SRS) or surgical resection as the primary treatment, were identified at Shanghai Chest Hospital. RESULTS: A total of 76 patients (22 patients underwent brain surgery as primary treatment and 54 patients received SRS) were available for survival analysis. The overall survival (OS) for patients treated with SRS and brain surgery as the primary treatment were 12.6 months (95% confidence interval [CI] 10.3–14.9) and 16.4 months (95% CI 8.8–24.1), respectively (adjusted hazard ratio =0.59, 95% CI 0.33–1.07, P=0.08). Among 76 patients treated with SRS or brain surgery, 21 patients who underwent primary tumor resection did not experience a significantly improved OS (16.4 months, 95% CI 9.6–23.2), compared with those who did not undergo resection (11.9 months, 95% CI 9.7–14.0; adjusted hazard ratio =0.81, 95% CI 0.46–1.44, P=0.46). Factors associated with survival benefits included stage I–II of primary lung tumor and solitary brain metastasis. CONCLUSION: There was no significant difference in OS for patients with synchronous brain oligometastasis receiving SRS or surgical resection. Among this population, the number of brain metastases and stage of primary lung disease were the factors associated with a survival benefit.
format Online
Article
Text
id pubmed-4948689
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49486892016-07-28 Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy Bai, Hao Xu, Jianlin Yang, Haitang Jin, Bo Lou, Yuqing Wu, Dan Han, Baohui Onco Targets Ther Original Research INTRODUCTION: Clinical evidence for patients with synchronous brain oligometastatic non-small-cell lung carcinoma is limited. We aimed to summarize the clinical data of these patients to explore the survival prognostic factors for this population. METHODS: From September 1995 to July 2011, patients with 1–3 synchronous brain oligometastases, who were treated with stereotactic radiosurgery (SRS) or surgical resection as the primary treatment, were identified at Shanghai Chest Hospital. RESULTS: A total of 76 patients (22 patients underwent brain surgery as primary treatment and 54 patients received SRS) were available for survival analysis. The overall survival (OS) for patients treated with SRS and brain surgery as the primary treatment were 12.6 months (95% confidence interval [CI] 10.3–14.9) and 16.4 months (95% CI 8.8–24.1), respectively (adjusted hazard ratio =0.59, 95% CI 0.33–1.07, P=0.08). Among 76 patients treated with SRS or brain surgery, 21 patients who underwent primary tumor resection did not experience a significantly improved OS (16.4 months, 95% CI 9.6–23.2), compared with those who did not undergo resection (11.9 months, 95% CI 9.7–14.0; adjusted hazard ratio =0.81, 95% CI 0.46–1.44, P=0.46). Factors associated with survival benefits included stage I–II of primary lung tumor and solitary brain metastasis. CONCLUSION: There was no significant difference in OS for patients with synchronous brain oligometastasis receiving SRS or surgical resection. Among this population, the number of brain metastases and stage of primary lung disease were the factors associated with a survival benefit. Dove Medical Press 2016-07-11 /pmc/articles/PMC4948689/ /pubmed/27471395 http://dx.doi.org/10.2147/OTT.S106696 Text en © 2016 Bai et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Bai, Hao
Xu, Jianlin
Yang, Haitang
Jin, Bo
Lou, Yuqing
Wu, Dan
Han, Baohui
Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
title Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
title_full Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
title_fullStr Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
title_full_unstemmed Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
title_short Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
title_sort survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948689/
https://www.ncbi.nlm.nih.gov/pubmed/27471395
http://dx.doi.org/10.2147/OTT.S106696
work_keys_str_mv AT baihao survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy
AT xujianlin survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy
AT yanghaitang survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy
AT jinbo survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy
AT louyuqing survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy
AT wudan survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy
AT hanbaohui survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy